Recent advances in cancer immunotherapy

Cite This

Files in this item

Checksum: MD5:fc4c103adbe65735b62e2d94de659ce7

SUN, Qiang, Gerry MELINO, Ivano AMELIO, Jingting JIANG, Ying WANG, Yufang SHI, 2021. Recent advances in cancer immunotherapy. In: Discover Oncology. Springer New York. 12(1), 27. ISSN 1868-8497. eISSN 1868-8500. Available under: doi: 10.1007/s12672-021-00422-9

@article{Sun2021-12Recen-56461, title={Recent advances in cancer immunotherapy}, year={2021}, doi={10.1007/s12672-021-00422-9}, number={1}, volume={12}, issn={1868-8497}, journal={Discover Oncology}, author={Sun, Qiang and Melino, Gerry and Amelio, Ivano and Jiang, Jingting and Wang, Ying and Shi, Yufang}, note={Article Number: 27} }

<rdf:RDF xmlns:dcterms="" xmlns:dc="" xmlns:rdf="" xmlns:bibo="" xmlns:dspace="" xmlns:foaf="" xmlns:void="" xmlns:xsd="" > <rdf:Description rdf:about=""> <dc:date rdf:datatype="">2022-02-09T10:31:59Z</dc:date> <dcterms:available rdf:datatype="">2022-02-09T10:31:59Z</dcterms:available> <dc:contributor>Amelio, Ivano</dc:contributor> <dc:language>eng</dc:language> <dc:creator>Wang, Ying</dc:creator> <bibo:uri rdf:resource=""/> <dc:creator>Amelio, Ivano</dc:creator> <dc:creator>Shi, Yufang</dc:creator> <dspace:isPartOfCollection rdf:resource=""/> <dcterms:isPartOf rdf:resource=""/> <dc:contributor>Jiang, Jingting</dc:contributor> <dcterms:abstract xml:lang="eng">Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.</dcterms:abstract> <dc:creator>Melino, Gerry</dc:creator> <dc:creator>Sun, Qiang</dc:creator> <dspace:hasBitstream rdf:resource=""/> <dc:creator>Jiang, Jingting</dc:creator> <dcterms:hasPart rdf:resource=""/> <dc:contributor>Sun, Qiang</dc:contributor> <dc:rights>Attribution 4.0 International</dc:rights> <dcterms:issued>2021-12</dcterms:issued> <dc:contributor>Wang, Ying</dc:contributor> <dcterms:rights rdf:resource=""/> <dcterms:title>Recent advances in cancer immunotherapy</dcterms:title> <dc:contributor>Melino, Gerry</dc:contributor> <dc:contributor>Shi, Yufang</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> </rdf:Description> </rdf:RDF>

Downloads since Feb 9, 2022 (Information about access statistics)

Sun_2-15vis3cdtrm3r2.pdf 71

This item appears in the following Collection(s)

Attribution 4.0 International Except where otherwise noted, this item's license is described as Attribution 4.0 International

Search KOPS


My Account